Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 1/20 | 0.42 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.42 |
| ▸ | FAAH | O00519 | 1/20 | 0.32 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5857183 | 1.00 | CYP4F2 (0.42) | CYP4F2CYP4A11FAAHDGAT1TSHR | |
| SCHEMBL5857558 | 1.00 | CYP4F2 (0.42) | CYP4F2CYP4A11FAAHDGAT1TSHR | |
| SCHEMBL5855517 | 1.00 | CYP4F2 (0.42) | CYP4F2CYP4A11FAAHDGAT1TSHR | |
| SCHEMBL5855704 | 0.82 | CYP4F2 (0.64) | CYP4F2CYP4A11FAAHTSHRALDH1A1 | |
| SCHEMBL4919828 | 0.79 | CYP4F2 (0.46) | CYP4F2CYP4A11DGAT1TSHRALDH1A1 | |
| SCHEMBL20254061 | 0.79 | CYP4A11 (0.54) | CYP4F2CYP4A11DGAT1TSHR | |
| SCHEMBL20057255 | 0.79 | CYP4F2 (0.42) | CYP4F2CYP4A11DGAT1TSHRALDH1A1 | |
| SCHEMBL5857277 | 0.77 | ALDH1A1 (0.50) | CYP4F2CYP4A11TSHRALDH1A1LMNA | |
| SCHEMBL5855843 | 0.77 | ALDH1A1 (0.50) | CYP4F2CYP4A11TSHRALDH1A1LMNA | |
| SCHEMBL5858394 | 0.77 | ALDH1A1 (0.50) | CYP4F2CYP4A11TSHRALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7144906-B2 | Heterocyclic compounds | NIPPON SHINYAKU CO., LTD. (JP) | 2006-12-05 | — | — | US | disclosed |
| US-7030143-B2 | Heterocyclic compounds | NIPPON SHINYAKU CO., LTD. (JP) | 2006-04-18 | — | — | US | disclosed |
| US-7022723-B2 | Heterocyclic compounds | NIPPON SHINYAKU CO., LTD. (JP) | 2006-04-04 | — | — | US | disclosed |
| EP-1634876-A2 | Heterocyclic compounds for the treatment of hyperlipidemia agents | Nippon Shinyaku Co., Ltd. (JP) | 2006-03-15 | — | — | EP | disclosed |
| US-6998412-B2 | Heterocyclic compounds | NIPPON SHINYAKU CO., LTD. (JP) | 2006-02-14 | — | — | US | disclosed |
| CN-1238347-C | Heterocyclic derivatives | NIPPON SHINYAKU CO LTD (JP) | 2006-01-25 | — | — | CN | disclosed |
| US-20050009892-A1 | Heterocyclic compounds | NIPPON SHINYAKU CO., LTD. (JP) | 2005-01-13 | — | — | US | disclosed |
| US-20050009785-A1 | Heterocyclic compounds | KUWABARA KENJI (JP) | 2005-01-13 | — | — | US | disclosed |
| US-20040162325-A1 | Heterocyclic compounds | KUWABARA KENJI (JP) | 2004-08-19 | — | — | US | disclosed |
| US-20030166697-A1 | Heterocyclic compounds | NIPPON SHINYAKU CO., LTD. (JP) | 2003-09-04 | — | — | US | disclosed |
| CN-1430612-A | Hete rocyclic derivatives | NIPPON SHINYAKU CO LTD (JP) | 2003-07-16 | — | — | CN | disclosed |
| EP-1295875-A1 | HETEROCYCLIC COMPOUNDS | Nippon Shinyaku Co., Ltd. (JP) | 2003-03-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009785-A1 | Heterocyclic compounds | LIPC, GPR119, APOB | CYP4F2 633/4885CYP4A11 118/4885FAAH 910/4885 |
| US-20050009892-A1 | Heterocyclic compounds | GPR119, LIPC, LIPE | CYP4F2 733/4885CYP4A11 118/4885FAAH 831/4885 |
| US-20040162325-A1 | Heterocyclic compounds | LIPE, GPR119, LIPC | CYP4F2 727/4885CYP4A11 126/4885FAAH 633/4885 |
| US-20030166697-A1 | Heterocyclic compounds | LIPE, GPR119, LIPC | CYP4F2 727/4885CYP4A11 126/4885FAAH 633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.